Condition
Cold Contact Urticaria
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04548869Phase 1Completed
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT02171416Phase 2CompletedPrimary
Cold Contact Urticaria Treatment With Rilonacept
NCT01580592Phase 2CompletedPrimary
Cold Urticaria Treatment With Xolair
NCT01605487Phase 2CompletedPrimary
Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria
NCT01271075Phase 2CompletedPrimary
Bilastine Updosing - Characterization of Underlying Mechanisms
Showing all 5 trials